Monobactams
Key Points
- Monobactams are bactericidal beta-lactam antibiotics that inhibit bacterial cell-wall synthesis.
- They are generally narrow-spectrum, used primarily for gram-negative organisms such as Pseudomonas aeruginosa.
- Prototype in this source is aztreonam, which may be administered IM, IV, or via inhalation.
- Screen severe beta-lactam allergy history before administration.
- Monitor for GI effects, rash, and coagulation-related concerns, plus superinfection findings (C. diff or candidiasis).
- Reassess treatment suitability when culture results identify organisms outside monobactam coverage (for example MRSA).
Mechanism of Action
Monobactams inhibit bacterial cell-wall synthesis and are generally bactericidal against susceptible organisms.
Clinical Use
- Primary use for selected gram-negative infections.
- Common use context includes suspected or confirmed Pseudomonas infection.
Nursing Considerations
- Check severe allergy history to beta-lactam classes before first dose.
- Monitor infection response using WBC trend, fever trend, infection-site assessment, and culture results.
- Evaluate ongoing organism coverage as definitive culture results return.
- Recognize that monobactam therapy may not be effective when cultures indicate resistant gram-positive organisms.
Side Effects and Adverse Effects
- Common: nausea, vomiting, diarrhea, abdominal pain.
- Other: skin rash and altered metallic/sour taste.
- Monitor for superinfection patterns including foul-smelling loose stools and yeast symptoms.
Health Teaching
- Report loose or foul-smelling stool, vaginal itching/discharge, fever, or bloody diarrhea immediately.
- Notify the provider if symptoms worsen or allergic-response signs appear.
- Do not delay communication when culture results suggest mismatch between organism and current antibiotic coverage.
Related Concepts
- antibiotics - Broader antibacterial therapy framework.
- culture-and-sensitivity-testing-in-infection-management - Confirms organism susceptibility and guides regimen adjustment.
- clostridioides-difficile-infection - Superinfection risk during antimicrobial use.
- carbapenems - Broader-spectrum beta-lactam alternative class.
Self-Check
- Why are monobactams not usually first-choice therapy for gram-positive organisms such as MRSA?
- Which monitoring findings should prompt early reassessment of aztreonam effectiveness?
- What patient-education points reduce delayed recognition of monobactam-related adverse effects?